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Abstract
Unlike normal cells, cancer cells express high levels of phosphatidylserine on the extracellular leaflet of their cell
membrane. Exploiting this characteristic, our lab developed a therapeutic agent that consists of the fusogenic protein,
saposin C (SapC) which is embedded in dioleoylphosphatidylserine (DOPS) vesicles. These nanovesicles selectively
target cancer cells and induce apoptosis. Here we review the data supporting use of SapC-DOPS to locate tumors for
surgical resection or for treatment. In addition, there is important evidence suggesting that SapC-DOPS may also prove
to be an effective novel cancer therapeutic reagent. Given that SapC-DOPS is easily labeled with lipophilic dyes, it has
been combined with the far-red fluorescent dye, CellVue Maroon (CVM), for tumor targeting studies. We also have
used contrast agents incorporated in the SapC-DOPS nanovesicles for computed tomography and magnetic resonance
imaging, and review that data here. Administered intravenously, the fluorescently labeled SapC-DOPS traversed
the blood–brain tumor barrier enabling identification of brain tumors. SapC-DOPS-CVM also detected a variety of
other mouse tumors in vivo, rendering them observable by optical imaging using IVIS and multi-angle rotational
optical imaging. Dye is detected within 30 min and remains within tumor for at least 7 days, whereas non-tumor
tissues were unstained (some dye observed in the liver was transient, likely representing degradation products).
Additionally, labeled SapC-DOPS ex vivo delineated tumors in human histological specimens. SapC-DOPS can also
be labeled with contrast reagents for computed tomography or magnetic resonance imaging. In conclusion,
labeled SapC-DOPS provides a convenient, specific, and nontoxic method for detecting tumors while
concurrently offering a therapeutic benefit.
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Background
Phosphatidylserine and cancer
Phospholipids are arranged asymmetrically in cell mem-
branes, with neutral phospholipids on the outer leaflet
and anionic phospholipids, such as phosphatidylethanol-
amine and phosphatidylserine (PS), located primarily on
the inner leaflet of the membrane [1–3]. A translocase,
the flippase complex, selective for PE and PS, is an ATP-
dependent pump that catalyzes rapid inward migration
of these phospholipids [1] to maintain this configuration.
Collapse of this asymmetry is an early process in apop-
tosis that results in the translocation of PS to the
exterior of the cell. In a normal cell undergoing apop-
tosis, the externalized PS serves as a trigger for phago-
cytes, particularly macrophages, to engulf the cell,
minimizing inflammation [4, 5].
Although cancer cells and their associated tumor vascu-
lature also exhibit a high level of PS on the outer leaflet
[6–9], this externalized phospholipid is not associated with
apoptosis. Critically, the mechanisms by which cancer cells
actually resist phagocytosis remain incompletely under-
stood [9]. Compared with non-malignant cells, expression
of PS on the cell surface is a consistent marker of malig-
nancy in both primary and metastatic cell lines [6–12]. In
their study focused on difficult-to-treat primary cancers,
including metastatic melanoma, glioblastoma, and meta-
static lesions, Riedl et al. [11] demonstrated the specificity
of abundant externalized PS for malignant tumors. While
virtually all cancer cells exhibit high external PS com-
pared with normal cells, the quantity of surface PS var-
ies widely among different cancer cells, even of the
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same type [10, 12]. The increase in surface PS has led
to the use of a number of proteins or peptides that bind
to PS to study apoptotic and tumor cells [2, 4, 13];
among these are annexin A5 (ANXA5), an endogenous
anticoagulant protein, and lactadherin (MFGE8) [2, 14],
a major glycoprotein in milk that promotes cellular ad-
hesion. Additionally, monoclonal antibodies to PS have
been generated that demonstrate anti-tumor activity [6,
15]. All of these have been conjugated to a number of
markers to detect the location of PS.
In this review, we discuss Saposin C-Dioleoylphosphati-
dylserine (SapC-DOPS), a stable nanovesicle that specifically
binds PS but, importantly, also has demonstrated thera-
peutic properties against a variety of cancer types. Given the
specificity of SapC-DOPS for cells that have undergone neo-
plastic transformation and the resultant enhancement seen
on imaging studies owing to the externalization of PS on
cancer cells, we review this new paradigm for improved
diagnosis and early detection of malignancy that may over-
come some of the limitations of current imaging related to
the cancer’s type and site or to other underlying medical
conditions (e.g., diabetes and kidney disease).
SapC-DOPS
Saposin C (SapC) is a small, fusogenic glycoprotein that is
remarkably heat-stable and protease-resistant [16–19].
While SapC itself is non-enzymatic, it is an activator of
lysosomal enzymes, particularly acid sphingomyelinase
and acid beta-glucosidase, which catalyze the breakdown
of sphingomyelin and glucosylceramide into phosphocho-
line and ceramide, and glucose and ceramide, respectively
[20–22]. Although the precise mechanism is unclear, this
increase in ceramide levels may result in cell death, as cer-
amide has been previously implicated in apoptosis [23],
possibly through the actions of caspases [24]. In order for
SapC to activate these enzymes, it must bind the PS of the
intracellular vesicles’ membranes. In vitro, at low pH,
SapC and dioleoylphosphatidylserine (DOPS) will spon-
taneously form nanovesicles with a mean diameter of
approximately 200 nm (Fig. 1). The amino- and carboxyl
termini of SapC are amphipathic helices that insert into
the lipid bilayer, while the middle region is exposed to
solvent. Conformational changes of SapC induced by PS
interaction suggest a reorientation of the functional helical
domains [25]. Importantly, the cytotoxicity of SapC-DOPS
positively correlates with the level of surface PS: the higher
the external PS, the more effectively SapC-DOPS [10, 12]
will bind the cell and trigger the ceramide cascade, ultim-
ately resulting in apoptosis (Fig. 2).
Main Text
Use of SapC-DOPS as a tumor detection agent
Histological sections
In our lab, the role of PS as a tumor marker has
been validated repeatedly for a variety of cancer types
[10, 24, 26–30]. In particular, the targeting of PS by SapC-
DOPS was demonstrated to be a novel method to achieve
accurate and effective identification of cancer cells. The
validation of PS as a reliable tumor marker, coupled with
the high affinity of SapC-DOPS for PS on a variety of can-
cer cell surfaces, provides a promising advancement for
accurate detection of several cancer types.
The lipophilic properties of SapC-DOPS make it an ideal
carrier of detection moieties, such as fluorescent markers
or clinically applicable contrast agents (Fig. 3). Experi-
ments coupling SapC-DOPS to the far-red fluorescent
probe CellVue Maroon (CVM) have been performed to
distinguish neoplastic tumor regions on histologic slides
and individual patient-derived neoplastic cell lines, as well
as in vivo [10, 24, 26–28, 31]. In several studies showing
the specificity of this reagent, SapC-DOPS-CVM was in-
ternalized by live tumor cells but not normal cells, clearly
Fig. 1 Generation of SapC-DOPS. Saposin C (SapC) is a low molecular weight, heat-stable protein which can fuse lipid vesicles into cells by binding to
phosphatidylserine (PS) in an acidic environment. Mixing SapC with dioleoylphosphatidylserine (DOPS) at a low pH results in the formation of
SapC-DOPS vesicles with a mean diameter of ~200 nm. Used with permission © 2015 Glia Media
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delineating the tumor in tissue slices. A caveat of using
histological slides is that their generation requires slicing
the cells, so that SapC-DOPS or other PS detection agents
will bind to PS on both the exterior and interior of the
membrane. However, fluorescently labeled SapC-DOPS
can be used with flow cytometry to distinguish only the
externalized PS.
Of particular interest is the role of SapC-DOPS in de-
tecting cancers that pose diagnostic challenges because
of the tumor site or the intrinsic properties of the malig-
nancy itself, by targeting surface PS of cancer cells and
tumor vessels. Such cancers include glioblastoma and
pancreatic adenocarcinoma, each of which carries a dev-
astating prognosis despite years of diagnostic and thera-
peutic research.
Fluorescent SapC-DOPS detection in mice
Previous studies have taken in vitro data of fluorescently
labeled SapC-DOPS a step further by evaluating diag-
nostic efficacy in vivo using mouse models. In one such
study, mice bearing human neuroblastoma xenografts
were injected intravenously with four different reagents:
(1) SapC-DOPS conjugated to CVM, (2) unconjugated
SapC and CVM, (3) DOPS and CVM, or (4) PBS alone
[24]. The mice then underwent optical imaging at time in-
tervals ranging from 0 to 48 h post-injection. The SapC-
DOPS-CVM fluorescent signal was diffuse between 0 and
5 h, and had accumulated specifically within the tumor re-
gion by 24 h, persisting for up to 100 h. However, there
was no fluorescence signal when uncoupled SapC was ad-
ministered with DOPS-CVM [24]. Similar results were
Fig. 2 Mechanism of cancer cell killing by SapC-DOPS. SapC-DOPS binds to PS-rich patches of cell membranes. Once SapC-DOPS binds, SapC
activates acid sphingomyelinase to initiate the ceramide cascade, which results in cell death. Used with permission © 2015 Glia Media
Fig. 3 Tumor detection by SapC-DOPS. SapC-DOPS nanovesicles can be labeled with imaging agents during formulation. For histological specimens
and in vivo studies with small animals, optical imaging with the far red fluorophore, CellVue Maroon (CVM) can be used. For in vivo MRI imaging, the
gadolinium chelate (Gd-DTAP-BSA) or the ultra-small cuperparamagnetic firon oxide (USPIO) can be incorporated and used as MRI contrast agents.
Used with permission © 2015 Glia Media
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demonstrated by Kaimal et al. [29] in their mouse xeno-
graft models of pancreatic adenocarcinoma and neuro-
blastoma and a murine rhabdomyosarcoma model. These
studies demonstrated the specificity of SapC-DOPS for
cells that have undergone neoplastic transformation, with
the consequent externalization of PS. As such, this is a
new paradigm for improved diagnosis and early detection
of malignancy.
In multi-angle rotational optical imaging (MAROI) to
detect SapC-DOPS-CVM in mice [32], we used a rota-
tional bed to obtain the in vivo image. Analysis of the
MAROI signal curve provided multispectral and multi-
modal data derived from complete rotational coverage.
We confirmed that optimal imaging depended on correct
orientation during positioning; the fluorescence intensity
decreased by as much as 9–12 % with each 10°of move-
ment. Use of anatomical landmarks and concurrent X-ray
imaging achieved both in vivo localization of the tumor
and quantitation of fluorescent marker intensity. These
findings can then be used in longitudinal studies to correl-
ate fluorescent signal distribution directly with mapping
of tumor location.
Impediments to clinical detection of malignancy using
mulimodality imaging
Among the factors considered when determining an opti-
mal treatment plan for patients diagnosed with cancer, es-
pecially important are the size and location of the primary
tumor and the extent of metastatic disease, if present. To
define these characteristics and facilitate treatment, effect-
ive imaging modalities currently available include com-
puted tomography (CT), positron emission tomography
(PET), and magnetic resonance imaging (MRI). Each mo-
dality can help define cancer staging and diagnosis, but
can also be limited in its effectiveness, depending on the
type and site of the cancer or the patient’s underlying
medical conditions. When such limitations exist, invasive
procedures or a combination of diverse imaging
techniques may be needed to make a definitive diagno-
sis; this can be both time-consuming and cost prohibi-
tive (see Table 1).
CT has played a pivotal role in both diagnosis and sta-
ging of malignancy for several years. Although CT has
been successful in upstaging many cancers at the time of
diagnosis to improve treatment outcomes, several limita-
tions prevent its universal applicability in cancer diagnosis,
particularly in cases of local, microscopic disease spread.
In a study of 957 lymph nodes evaluated from patients
with head and neck cancers, Don et al. [33] found that
20 % of malignant lymph nodes had extracapsular spread;
almost one third of these nodes were smaller than 10 mm,
which is the size cut-off used to define pathological adeno-
pathy on radiographic review. In addition, central necro-
sis, a common characteristic used to identify malignant
lymph nodes by CT, were found primarily in lymph nodes
that were 20 mm or larger, suggesting that central necrosis
is a late event in metastatic adenopathy. Such findings
suggest a deficiency in our ability to detect metastatic dis-
ease early in its course [33].
In contrast with CT and MRI, detection by PET im-
aging has proven superior for regional nodal and distant
metastases, but inferior for several primary malignancies
[34]. Moreover, PET has very poor spatial resolution,
limiting accurate biopsy because of poor localization of
the potential malignancy. While this problem can be off-
set in part by combined PET-CT scanning, defects in
registration between the signals can still pose problems
with tumor localization [34].
As such, currently available imaging modalities present
shortcomings in our ability to detect occult spread of ma-
lignancy, which inevitably leads to delays in diagnosis of
metastatic disease until it has spread more widely. At that
point, few treatment options may remain. Such studies
highlight the need for sensitive imaging techniques that
focus on specifically revealing malignant cells, rather than
probing tentative neoplastic properties of lymph nodes that
may imply, but are not always specific for, malignancy.
Table 1 Comparison of non-invasive imaging procedures for cancer detection
Imaging method Benefits Limitations
Optical Imaging Fluorescently labeled probes
may be sensitive and specific
Limited depth, may be too specific, may require a visit to inject the
probe with a follow-up visit to detect where it binds
Computed Tomography (CT) Fast, highly detailed Exposure to ionizing radiation, may not be able to differentiate
tumor from other lesions, may not detect small tumors, may
require potentially toxic contrast agents, not ideal modality for
brain tumor detection
Magnetic Resonance Imaging (MRI) Used for detection of brain tumors,
no radiation exposure for patient
Prolonged acquisition time, metal implants preclude this technique,
requires potentially toxic contrast agents
Positron Emission Tomography (PET) Better than CT or MRI for nodal or
distant metastases
Poor special resolution, inferior for detection of primary tumors,
cannot detect brain tumors, use of FDG impacted in diabetics,
exposure to ionizing radiation
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Detection of intracranial neoplasms, such as glioblastoma
multiforme, also poses a diagnostic challenge by currently
available imaging techniques. PET imaging, for example, re-
lies on underlying tissue metabolism to detect malignancy,
given that neoplastic cells have increased metabolic activity
compared with normal tissue. Non-malignant brain tissue,
however, has metabolic activity comparable to tumors
found in areas outside of the brain. Because intracranial
neoplasms cannot be accurately identified on PET im-
aging, a second mode of imaging is needed to detect
either primary or metastatic disease in the brain. Similarly,
a CT of the brain can delineate brain lesions but often can-
not definitively distinguish neoplastic tumors from other
causes of brain lesions, including infections or demyelinat-
ing diseases. Therefore, detection of intracranial malig-
nancy currently relies on MRI for evaluation and
characterization. Such studies, however, require prolonged
acquisition time, which can cause increased motion artifact
and result in poor image quality unless the patient is se-
dated, as for pediatric patients, which increases patient risk.
Beyond accurate detection of malignancy, limitations in
current imaging modalities also relate to any underlying
medical conditions of the patient. For example, CT im-
aging often requires an intravenous contrast agent. Con-
trast can be particularly nephrotoxic for patients with
acute or chronic kidney disease. This comorbidity is com-
mon in patients at the time of cancer diagnosis because of
poor oral intake and prolonged cachexia, and can also be a
frequent consequence of several chemotherapeutic regi-
mens. Thus, contrast-enhanced CT imaging is commonly
avoided in patients with underlying kidney disease. Similar
caution must be taken when using gadolinium contrast for
MRI in patients with kidney disease because of the possi-
bility of adverse outcomes, such as nephrogenic systemic
sclerosis, which carries a high rate of morbidity and mor-
tality. Limitations in PET imaging occur in diabetic pa-
tients, because blood glucose levels can significantly
impact tumor uptake of fluorodeoxyglucose (FDG), the
agent used to detect malignancy. In these cases, FDG
and glucose compete for glucose transport and phos-
phorylation [35]. Guidelines currently require both
tight glycemic control (i.e., glucose levels below
200 mg/dL) before PET imaging and that patients ab-
stain from all glucose-containing food and drink for at
least 6 h prior to the study. However, these restrictions
have often proven difficult to achieve, thus compromis-
ing imaging quality and accuracy. Advances in com-
bined PET/CT [36] and PET/MRI [37] have solved
some of these problems. However, the toxicity of con-
trast agents and their inability to cross the blood–brain
barrier limit their effectiveness and demonstrate the ne-
cessity for a diagnostic agent with limited side effects,
few clinical restrictions, and enhanced specificity for
neoplastic cells.
Detection of malignancy using SapC-DOPS in preclinical
studies
To improve MRI sensitivity, shorten scanning time, and
improve safety, we have used SapC-DOPS as a carrier for
contrast agents. The method of Bogdanov et al. [38] was
implemented to encapsulate ferumoxtran-10, an ultra-small
super-paramagnetic iron oxide (USPIO) contrast agent, into
SapC-DOPS vesicles. The resulting SapC-DOPS-USPIO
was used with MRI to detect tumors in mice [29]. The T2
relaxation time (i.e., time for the transverse magnetization
to fall to approximately 37 % of its initial value after
magnetization) of subcutaneous xenografts of neuroblasto-
mas or pancreatic tumors was decreased by SapC-DOPS-
USPIO, thus indicating the uptake of the agent by tumors.
This allowed specific detection of the malignancy (Fig. 4a).
Additionally, we incorporated the paramagnetic con-
trast agent, gadolinium, into SapC-DOPS vesicles by
using the lipophilic gadolinium chelate, gadolinium-
DTPA-bis (stearylamide) [39]. These vesicles produced
a 9 % increase in the longitudinal relaxation rate (R1)
of orthotopic glioblastoma multiforme tumors in mice
within 10 h post-injection, but only minimal changes in
normal brain tissue; again this demonstrated improved
specificity of tumor detection.
We have recently used a phenol-substituted lipophilic
dye to label SapC-DOPS with 124I, a positron emitter.
We then used this labeled SapC-DOPS for PET imaging.
As shown in Fig. 4b we were able to selectively enhance
the intracranial glioblastomas with PET scanning [40].
Concurrent studies with SapC-DOPS labeled with 125I
instead of 124I indicated that SapC-DOPS specifically tar-
geted the tumor, although some label was detected in
the liver and spleen, likely disposal routes.
These studies indicate the ability of SapC-DOPS to
transverse the blood brain barrier without requiring either
alteration of the barrier or direct intracranial administra-
tion of the agent [12]. This suggests a potential role for
SapC-DOPS in improving the safety and convenience of
detecting (and treating) intracranial neoplasms.
The pharmacologic safety of SapC-DOPS has been eval-
uated in mice at 12× the typical therapeutic dose of 4 mg/
kg of Sap C and 2 mg/kg of DOPS [24]. Even at these
levels, no acute toxicity or weight loss was demonstrated
with administration. Furthermore, histological examin-
ation of vital organs (i.e., lung, liver, spleen, kidney, heart,
brain) revealed neither damage nor toxic changes. Chronic
toxicity studies were also performed with injection of 2×
therapeutic concentrations of SapC-DOPS weekly for
5 weeks. Again, these studies demonstrated no significant
toxicity on histological review of the vital organs listed
above [24]. In comparison, the contrast agents currently
used for image enhancement during CT and MRI scan-
ning can place patients at risk for kidney damage or sys-
temic disease. Beyond the pharmacologic safety evidence,
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we compared survival data for mice with pancreatic tu-
mors treated with SapC-DOPS versus control groups.
Mice treated with SapC-DOPS lived significantly longer
compared with untreated control groups: specifically, all
control mice had died by 23 weeks after treatment, while
4 of the 6 SapC-DOPS-treated mice were still alive [10].
Similar results were obtained with a brain tumor model
[28]. Mice bearing orthotopic glioblastoma multiforme
that were treated with DOPS alone all died within 20 days.
However, 25 % of those treated with SapC-DOPS survived
at least 350 days. In addition, the tumors were smaller in
the SapC-DOPS treated mice. Again, these studies pro-
vide pre-clinical data to support the safety of systemic
SapC-DOPS administration for diagnostic and thera-
peutic purposes. Although there is some therapeutic value
of SapC-DOPS with the dose that would be injected for
diagnostic purposes, multiple doses are generally given to
shrink tumors. Additionally, as SapC-DOPS is a nanovesi-
cle it can be loaded with radioisotopes or chemotherapeu-
tic drugs to provide further benefit.
Conclusions
Our data indicate that the novel and PS-targeted nano-
vesicle, SapC-DOPS, can be used for exposure of hard to
detect malignancies, whether due to size or location. Al-
though further studies are required, our preclinical stud-
ies suggest that the tumor–selective nanovesicles may
greatly contribute to improving the precision of early
cancer diagnosis. In addition, SapC-DOPS may have a
therapeutic benefit and be used as a “theranostic” com-
pound. Ongoing studies are to provide support for the
inclusion of SapC-DOPS in the battery of tests con-
ducted by oncologists to enhance the accuracy and sen-
sitivity of tumor diagnosis.
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Fig. 4 a High-resolution MRI of a glioma in a mouse in vivo. MRI was performed at 7T. T2* weighted 3D FLASH sequence (TE/TR = 10 ms/20 ms/
FA = 10°) were used with a 320 × 320 × 64 matrix and 3.2 × 3.2 × 0.64 cm FOV resulting in an isotropic 100 mm resolution. Negative contrast enhancement
is observed 4 h following SapC-DOPS-USPIO (adapted from [28]). b MicroPET imaging of a glioblastoma in a mouse brain 24 h after administration of
SapC-DOPS-124I · (2a) nanovesicles. 2a is a phenol-substituted analog of indodicarbocyanine (DiD). A CT scan was acquired for anatomical co-registration
and attenuation correction of the PET data. Concurrent bioluminescence imaging (BLI) confirmed the presence of glioblastoma (adapted from [40]).
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